New Study Finds Apixaban Safe for Stroke Prevention During Ramadan Fasting (API-RAM Trial)
Ghada D. Mustafa, Cardiologist at Royal Brompton & Harefield Hospitals Specialist Care, shared a post by Leila Abid on LinkedIn:
”A truly valuable and timely study addressing a real clinical question that many of us encounter in practice , anticoagulation management during Ramadan fasting.
The API-RAM study, led by Prof. Leila Abid and colleagues in Tunisia, provides important evidence supporting the safety and efficacy of apixaban during fasting among patients with atrial fibrillation.
This work highlights the growing need for data that reflect our patients’ lived experiences and cultural contexts. Clinical recommendations must not only be evidence-based but also culturally relevant.
Congratulations to the authors on advancing region-specific cardiovascular research that bridges science and patient reality.”
Quoting Leila Abid‘s post:
”We are pleased to share our recent publication: “Safety and effectiveness of apixaban use for stroke prevention during Ramadan fasting (the API-RAM study)”, conducted in Tunisia by the cardiology department of Hedi Chaker university hospital of Sfax Led by Pr Leila Abid in collaboration with Pr. Faouzi Addad, PrSalem Abdessalem, Pr Ismail El Alamy and colleagues.
Key findings:
Among 257 patients included over two Ramadan seasons, no ischemic (stroke) events were reported
Apixaban, despite a twice-daily schedule, seems to maintain both safety and efficacy in this special setting. This gives support to clinicians advising patients with atrial fibrillation who wish to fast.”
Read the full article here.
Title: Safety and effectiveness of apixaban use for stroke prevention during Ramadan fasting (the API-RAM study)
Authors: Aiman Ghrab, Rania Gargouri, Faouzi Addad, Anis Cheikhrouhou, Mariem Jabeur, Selma Charfeddine, Amine Bahloul, Zied Triki, Tarek Ellouze, Omar Abidi, Souad Mallek, Faten Triki, Salem Abdessalem, Ismail Elalamy, Leila Abid
Stay updated with Hemostasis Today.
-
Oct 10, 2025, 16:15Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
-
Oct 10, 2025, 12:21Chris Barber Echoes PPTA’s Call to Recognize the Lifesaving Work of Plasma Collection Teams Worldwide
-
Oct 10, 2025, 12:14William Aird: Thalassemia Trait is a Quiet Experiment of Nature
-
Oct 9, 2025, 19:53Wilfried Dinh: Top 10 Thrombosis And Antithrombotic Therapy Papers Of 2024
-
Oct 9, 2025, 13:12Abdul Mannan - Ferritin After IV Iron: Timing Matters
-
Oct 10, 2025, 12:23Bhavya Venkatesh: Talin Autoinhibition Is Required For Normal Hemostasis
-
Oct 10, 2025, 12:19Divyaswathi Citla Sridhar: Excited to Share Our Multicenter Study on Platelet Function Disorders, Now Published
-
Oct 10, 2025, 12:18Roberta Gualtierotti: We Evaluated Different Variables of the Cleaved HK Method in C1-Inhibitor Defects
-
Oct 10, 2025, 12:17Jamie Madrigal And The Team - Mathematical Analysis Of Emicizumab: Affinity-Driven Complex Formation And Lipid-Surface Reactions
-
Oct 10, 2025, 03:09Giuseppe Lippi: We Show Here That Red Light Therapy Offers Promise in High-Risk Patients
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?
-
Oct 10, 2025, 03:06Anita Brikman: Increasing Awareness of The Ongoing Need for Plasma Donors Is Vital to Ensuring Patient Access and Continuity of Care
-
Oct 10, 2025, 03:04Stephen Cornelissen: A New Plasma Drop Has Been Added to Lifeblood’s Blood Supply Tracker
-
Oct 10, 2025, 02:12Bethany Samuelson Bannow Welcomed to Department of Hematology and Medical Oncology at the Cancer Institute Cleveland Clinic